Nevertheless, the multicenter retrospective study of CCA patients mentioned above also reported enhanced OS of CCA patients harboring somatic mutations suspected to be pathogenic in BRCA1/2 when treated with platinum-based therapy[132]. The gene discussed is BRCA1; the disease is cholangiocarcinoma.